Change of Registered Address

RNS Number : 0119F
Oxford Biomedica PLC
16 February 2015
 



 

 

 

 

 

 

Oxford BioMedica: Change of Registered Address

 

 

Oxford, UK - 16 February 2015: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene and cell therapy company, announces that the registered office address of the Company has changed to:

 

Oxford BioMedica Plc
Windrush Court
Transport Way
Oxford
OX4 6LT

 

The registered address at Companies House has been changed with immediate effect.

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/ Matthew Neal/ Chris Welsh/ Laura Thornton

Consilium Strategic Communications

 

 

Tel: +44 (0)20 3709 5700

 

Notes to editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

CROGGUBWPUPAGGQ